Literature DB >> 15936771

The practical value of applying chemical biliary duct embolization to chemical hepatectomy for treatment of hepatolithiasis.

Fuyu Li1, Jingqiu Cheng, Sheng He, Ning Li, Mingming Zhang, Jiahong Dong, Lisheng Jiang, Nansheng Cheng, Xianzhe Xiong.   

Abstract

BACKGROUND: The high recurrence rate of hepatolithiasis, together with the high operative risk of hepatectomy for specifically located stones, has not been effectively settled until now. Thus, the aim of this study was to investigate the feasibility and effectiveness of using chemical biliary duct embolization (CBDE) to achieve chemical hepatectomy in a rabbit model of hepatolithiasis.
MATERIALS AND METHODS: The animal model of hepatolithiasis was established using the methods of obstruction plus infection. Seven days later, the left hepatic ducts were embolized using phenol plus cyanoacrylate or absolute ethanol plus cyanoacrylate. Subsequently, the influence of CBDE on bile duct, liver, and stone formation was analyzed by histology, RT-PCR for procollagen, biochemistry, and enzymatic histochemistry for beta-glucuronidase (beta-G).
RESULTS: CBDE resulted in the entire ablation of the diseased biliary duct mucosa and the complete occlusion of the diseased biliary duct lumen, thus effectively eradicating chronic proliferative cholangitis and preventing stone formation. More importantly, CBDE also resulted in the complete fibrosis and "self-cut" in the periphery of the embolized lobe, thus achieving chemical hepatectomy. Also of note, the embolized lobe exhibited a much lower level of endogenous beta-G than the nonembolized lobe, indicating an inhibitory effect of CBDE on beta-G. Besides, the mRNA level of procollagen I in the embolized bile duct wall of phenol embolization group was significantly higher than the ethanol embolization group.
CONCLUSION: Chemical biliary duct embolization, especially using phenol plus cyanoacrylate, may prevent the recurrence of intrahepatic stone and concurrently achieve the effect of chemical hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936771     DOI: 10.1016/j.jss.2005.02.029

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Laparoscopic hepatectomy for hepatolithiasis: a feasibility and safety study in 29 patients.

Authors:  Xiujun Cai; Yifan Wang; Hong Yu; Xiao Liang; Shuyou Peng
Journal:  Surg Endosc       Date:  2007-05-22       Impact factor: 4.584

2.  Postoperative bile leakage managed successfully by intrahepatic biliary ablation with ethanol.

Authors:  Tetsuya Shimizu; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Satoshi Matsumoto; Yoshiaki Mizuguchi; Shigeki Yokomuro; Yasuo Arima; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Surgical treatment of complicated hepatolithiasis using the ultrasound-guided fiberoptic choledochoscope.

Authors:  Weidong Pan; Erjiao Xu; Heping Fang; Meihai Deng; Ruiyun Xu
Journal:  Surg Endosc       Date:  2010-07-08       Impact factor: 4.584

Review 4.  Significance of controlling chronic proliferative cholangitis in the treatment of hepatolithiasis.

Authors:  Fu Yu Li; Nan Sheng Cheng; Hui Mao; Li Sheng Jiang; Jing Qiu Cheng; Quan Sheng Li; Sanjay Munireddy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

5.  Treatment of chronic proliferative cholangitis with c-myc shRNA.

Authors:  Fu-Yu Li; Nan-Sheng Cheng; Jing-Qiu Cheng; Hui Mao; Li-Sheng Jiang; Ning Li; Sheng He
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

6.  Oddi sphincter preserved cholangioplasty with hepatico-subcutaneous stoma for hepatolithiasis.

Authors:  Yu-Gui Lian; Wei-Tao Zhang; Zhi Xu; Xiao-Feng Ling; Li-Xin Wang; Chun-Sheng Hou; Gang Wang; Long Cui; Xiao-Si Zhou
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

7.  Recurrent pyogenic cholangitis: disease characteristics and patterns of recurrence.

Authors:  Ye Xin Koh; Adrian Kah Heng Chiow; Aik Yong Chok; Lip Seng Lee; Siong San Tan; Salleh Ibrahim
Journal:  ISRN Surg       Date:  2013-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.